Literature DB >> 30896318

Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity.

Seda Kahraman1, Alev Eroglu Altinova2, Serenay Elgun3, Mehmet Muhittin Yalcin2, Banu Aktas Yilmaz2, Cigdem Ozkan2, Mujde Akturk2, Fusun Balos Toruner2.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) plays a role in metabolic and inflammatory diseases. Increased adenosine deaminase (ADA) has been suggested to induce insulin resistance and inflammation. We measured serum DPP-4 and ADA activities. Serum ADA activity was significantly higher in PCOS group (p = .006), whereas there was no difference in serum DPP-4 activity between the groups (p > .05). When the study subjects were divided into four groups in terms of obesity; an increasing trend in serum ADA activity between the groups was observed and ADA activity was significantly higher in overweight and obese patients with PCOS than nonobese controls (p = .016), there were no significant differences between the other groups (p > .05). A positive correlation was found between ADA and BMI in the whole group (p = .022). Multivariate regression analyses revealed that significant determinants were diastolic blood pressure, ADA, and the presence of PCOS for DPP-4 (R2 = 0.344, F = 9.079, p < .001); the presence of PCOS and DPP-4 for ADA (R2 = 0.123, F = 6.302, p = .003). We demonstrated increased serum ADA activity as well as its association with obesity in PCOS, while there was no change in serum DPP-4 activity in women with PCOS.

Entities:  

Keywords:  Adenosine deaminase; dipeptidyl peptidase-4; inflammation; obesity; polycystic ovary syndrome

Mesh:

Substances:

Year:  2019        PMID: 30896318     DOI: 10.1080/09513590.2019.1581165

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  1 in total

1.  Serum dipeptidyl peptidase-4 activity and progranulin level in polycystic ovary syndrome patients.

Authors:  Maryam Abolghasemi; Soleiman Mahjoub; Sedighe Esmaeilzadeh
Journal:  Caspian J Intern Med       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.